[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sheila K. Gujrathi M.D.", "age": 53, "title": "Executive Chairperson", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 125000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raju S. Mohan Ph.D.", "age": 65, "title": "Founder, CEO, President & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 905293, "exercisedValue": 0, "unexercisedValue": 219686}, {"maxAge": 1, "name": "Dr. John M. Nuss Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 630635, "exercisedValue": 0, "unexercisedValue": 451580}, {"maxAge": 1, "name": "Dr. Martin Douglas Auster M.D.", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Richard Moore", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.07, "open": 2.06, "dayLow": 1.9007, "dayHigh": 2.064, "regularMarketPreviousClose": 2.07, "regularMarketOpen": 2.06, "regularMarketDayLow": 1.9007, "regularMarketDayHigh": 2.064, "beta": 0.383, "forwardPE": -0.8812785, "volume": 837758, "regularMarketVolume": 837758, "averageVolume": 1108303, "averageVolume10days": 1226240, "averageDailyVolume10Day": 1226240, "bid": 1.9, "ask": 1.94, "bidSize": 400, "askSize": 100, "marketCap": 136391360, "fiftyTwoWeekLow": 1.865, "fiftyTwoWeekHigh": 38.2, "fiftyDayAverage": 2.7996, "twoHundredDayAverage": 4.230925, "currency": "USD", "enterpriseValue": -81887896, "floatShares": 51835808, "sharesOutstanding": 70669104, "sharesShort": 8642607, "sharesShortPriorMonth": 7948658, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.122600004, "heldPercentInsiders": 0.0317, "heldPercentInstitutions": 0.94797, "shortRatio": 8.37, "shortPercentOfFloat": 0.1436, "bookValue": 3.974, "priceToBook": 0.48565677, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -171302000, "trailingEps": -2.78, "forwardEps": -2.19, "enterpriseToEbitda": 0.441, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "VTYX", "underlyingSymbol": "VTYX", "shortName": "Ventyx Biosciences, Inc.", "longName": "Ventyx Biosciences, Inc.", "firstTradeDateEpochUtc": 1634823000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f523c464-d79a-3f62-beea-fdbd09f3b782", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.93, "targetHighPrice": 21.0, "targetLowPrice": 2.0, "targetMeanPrice": 10.67, "targetMedianPrice": 10.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 239438000, "totalCashPerShare": 3.388, "ebitda": -185548992, "totalDebt": 11265000, "quickRatio": 13.253, "currentRatio": 14.192, "debtToEquity": 4.012, "returnOnAssets": -0.35294, "returnOnEquity": -0.56294, "freeCashflow": -94251624, "operatingCashflow": -158482000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-12"}]